Literature DB >> 21326343

Time course in calpain activity and autolysis in slow and fast skeletal muscle during clenbuterol treatment.

Aymeric Douillard1, Olivier Galbes, Bernadette Rossano, Barbara Vernus, Anne Bonnieu, Robin Candau, Guillaume Py.   

Abstract

Calpains are Ca2+ cysteine proteases that have been proposed to be involved in the cytoskeletal remodeling and wasting of skeletal muscle. Cumulative evidence also suggests that β2-agonists can lead to skeletal muscle hypertrophy through a mechanism probably related to calcium-dependent proteolytic enzyme. The aim of our study was to monitor calpain activity as a function of clenbuterol treatment in both slow and fast phenotype rat muscles. For this purpose, for 21 days we followed the time course of the calpain activity and of the ubiquitous calpain 1 and 2 autolysis, as well as muscle remodeling in the extensor digitorum longus (EDL) and soleus muscles of male Wistar rats treated daily with clenbuterol (4 mg·kg-1). A slow to fast fiber shift was observed in both the EDL and soleus muscles after 9 days of treatment, while hypertrophy was observed only in EDL after 9 days of treatment. Soleus muscle but not EDL muscle underwent an early apoptonecrosis phase characterized by hematoxylin and eosin staining. Total calpain activity was increased in both the EDL and soleus muscles of rats treated with clenbuterol. Moreover, calpain 1 autolysis increased significantly after 14 days in the EDL, but not in the soleus. Calpain 2 autolysis increased significantly in both muscles 6 hours after the first clenbuterol injection, indicating that clenbuterol-induced calpain 2 autolysis occurred earlier than calpain 1 autolysis. Together, these data suggest a preferential involvement of calpain 2 autolysis compared with calpain 1 autolysis in the mechanisms underlying the clenbuterol-induced skeletal muscle remodeling.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21326343     DOI: 10.1139/y10-114

Source DB:  PubMed          Journal:  Can J Physiol Pharmacol        ISSN: 0008-4212            Impact factor:   2.273


  7 in total

1.  Acute supra-therapeutic oral terbutaline administration has no ergogenic effect in non-asthmatic athletes.

Authors:  Anthony M J Sanchez; Fabio Borrani; Marie Amélie Le Fur; Anais Le Mieux; Virgile Lecoultre; Guillaume Py; Christophe Gernigon; Katia Collomp; Robin Candau
Journal:  Eur J Appl Physiol       Date:  2012-07-06       Impact factor: 3.078

2.  Chronic clenbuterol treatment compromises force production without directly altering skeletal muscle contractile machinery.

Authors:  G Py; C Ramonatxo; P Sirvent; A M J Sanchez; A G Philippe; A Douillard; O Galbès; C Lionne; A Bonnieu; A Chopard; O Cazorla; A Lacampagne; R B Candau
Journal:  J Physiol       Date:  2015-02-27       Impact factor: 5.182

3.  Three calpain isoforms are autolyzed in rat fast-twitch muscle after eccentric contractions.

Authors:  Keita Kanzaki; Mai Kuratani; Satoshi Matsunaga; Noriyuki Yanaka; Masanobu Wada
Journal:  J Muscle Res Cell Motil       Date:  2014-02-21       Impact factor: 2.698

4.  Adverse effects from clenbuterol and ractopamine on nematode Caenorhabditis elegans and the underlying mechanism.

Authors:  Ziheng Zhuang; Yunli Zhao; Qiuli Wu; Min Li; Haicui Liu; Lingmei Sun; Wei Gao; Dayong Wang
Journal:  PLoS One       Date:  2014-01-21       Impact factor: 3.240

5.  Effects of chronic administration of clenbuterol on contractile properties and calcium homeostasis in rat extensor digitorum longus muscle.

Authors:  Pascal Sirvent; Aymerick Douillard; Olivier Galbes; Christelle Ramonatxo; Guillaume Py; Robin Candau; Alain Lacampagne
Journal:  PLoS One       Date:  2014-06-27       Impact factor: 3.240

6.  Role of phosphodiesterase 4 expression in the Epac1 signaling-dependent skeletal muscle hypertrophic action of clenbuterol.

Authors:  Yoshiki Ohnuki; Daisuke Umeki; Yasumasa Mototani; Kouichi Shiozawa; Megumi Nariyama; Aiko Ito; Naoya Kawamura; Yuka Yagisawa; Huiling Jin; Wenqian Cai; Kenji Suita; Yasutake Saeki; Takayuki Fujita; Yoshihiro Ishikawa; Satoshi Okumura
Journal:  Physiol Rep       Date:  2016-05

7.  β-arrestin 1 regulates β2-adrenergic receptor-mediated skeletal muscle hypertrophy and contractility.

Authors:  Jihee Kim; Chad A Grotegut; James W Wisler; Tianyu Li; Lan Mao; Minyong Chen; Wei Chen; Paul B Rosenberg; Howard A Rockman; Robert J Lefkowitz
Journal:  Skelet Muscle       Date:  2018-12-27       Impact factor: 4.912

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.